ASH Letter re FDA's Draft Guidance on Assessment of Overall Survival in Oncology Clinical Trials
Oct 17
2025
American Society of Hematology. (2025).
ASH Letter re FDA's Draft Guidance on Assessment of Overall Survival in Oncology Clinical Trials.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-assessment-of-overall-survival-in-oncology-clinical-trials.
American Society of Hematology.
"ASH Letter re FDA's Draft Guidance on Assessment of Overall Survival in Oncology Clinical Trials." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-assessment-of-overall-survival-in-oncology-clinical-trials
(label-accessed April 06, 2026).
"American Society of Hematology."
ASH Letter re FDA's Draft Guidance on Assessment of Overall Survival in Oncology Clinical Trials, 06 Apr. 2026 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-re-fdas-draft-guidance-on-assessment-of-overall-survival-in-oncology-clinical-trials.
